Topol EJ - Search Results

1

Unexpected mortality reduction with abciximab for in-stent restenosis.

Mukherjee D, Reginelli JP, Moliterno DJ, Yadav JS, Schneider JP, Raymond R, Whitlow PL, Franco I, Topol EJ, Ellis SG. Mukherjee D, et al. Among authors: topol ej. J Invasive Cardiol. 2000 Nov;12(11):540-4. J Invasive Cardiol. 2000. PMID: 11060563

2

Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction.

Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Chan AW, et al. Among authors: topol ej. Am J Cardiol. 2002 Jan 15;89(2):132-6. doi: 10.1016/s0002-9149(01)02188-9. Am J Cardiol. 2002. PMID: 11792330

3

Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting.

Ellis SG, Lincoff AM, Whitlow PL, Raymond RE, Franco I, Schneider JP, Topol EJ. Ellis SG, et al. Among authors: topol ej. Am J Cardiol. 2002 Apr 15;89(8):937-40. doi: 10.1016/s0002-9149(02)02242-7. Am J Cardiol. 2002. PMID: 11950431

4

Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention.

Chan AW, Quinn MJ, Bhatt DL, Chew DP, Moliterno DJ, Topol EJ, Ellis SG. Chan AW, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Aug 21;40(4):669-75. doi: 10.1016/s0735-1097(02)02013-2. J Am Coll Cardiol. 2002. PMID: 12204496 Free article.

5

Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.

Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Brener SJ, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Dec 4;40(11):1961-7. doi: 10.1016/s0735-1097(02)02538-x. J Am Coll Cardiol. 2002. PMID: 12475456 Free article.

6

Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry.

Brener SJ, Ellis SG, Schneider J, Apperson-Hansen C, Topol EJ. Brener SJ, et al. Among authors: topol ej. Eur Heart J. 2003 Apr;24(7):630-8. doi: 10.1016/s0195-668x(02)00812-6. Eur Heart J. 2003. PMID: 12657221

7

Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.

Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ. Casserly IP, et al. Among authors: topol ej. Am J Cardiol. 2003 Jul 15;92(2):125-9. doi: 10.1016/s0002-9149(03)00525-3. Am J Cardiol. 2003. PMID: 12860211 Clinical Trial.

8

Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization.

Chiu JH, Topol EJ, Whitlow PL, Hsu AP, Tuzcu EM, Franco I, Moliterno DJ. Chiu JH, et al. Among authors: topol ej. Am J Cardiol. 2003 Sep 1;92(5):582-3. doi: 10.1016/s0002-9149(03)00726-4. Am J Cardiol. 2003. PMID: 12943879

9

Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation.

Brener SJ, Bhatt DL, Moliterno DJ, Schneider JP, Ellis SG, Topol EJ. Brener SJ, et al. Among authors: topol ej. Am J Cardiol. 2003 Dec 15;92(12):1468-71. doi: 10.1016/j.amjcard.2003.08.063. Am J Cardiol. 2003. PMID: 14675590

10

The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.

Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ. Lee DS, et al. Among authors: topol ej. J Invasive Cardiol. 2004 Feb;16(2):46-51. J Invasive Cardiol. 2004. PMID: 14760188 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,220 results

Search Page

Filters